Literature DB >> 24519428

Sildenafil attenuates vaso-obliteration and neovascularization in a mouse model of retinopathy of prematurity.

Amani A Fawzi1, Jonathan C Chou, Gina A Kim, Stuart D Rollins, Joann M Taylor, Kathryn N Farrow.   

Abstract

PURPOSE: We sought to determine the effect of sildenafil on retinal vascular changes in a mouse model of oxygen-induced retinopathy (OIR).
METHODS: Vascular defects in OIR mice were quantified by measuring vaso-obliteration at postnatal days 12 and 17 (P12 and P17) and neovascularization at P17 to compare sildenafil-treated to dextrose-treated OIR mice. Retinal HIF1α protein expression was quantified by Western blotting and normalized to that of β-actin. Right ventricular hypertrophy was measured by Fulton's index as a surrogate for hyperoxia-induced pulmonary hypertension.
RESULTS: At P12, OIR mice treated with sildenafil demonstrated a 24% reduction in vaso-obliteration (P < 0.05), whereas at P17, treated animals showed a 50% reduction in neovascularization (P < 0.05) compared to dextrose-treated controls. Sildenafil-treated OIR mice had stabilization of retinal HIF1α at P12, immediately after hyperoxia. At P17, sildenafil-treated OIR mice had decreased HIF1α relative to untreated mice. OIR mice developed right ventricle hypertrophy that was significant compared to that in room air controls, which was abrogated by sildenafil.
CONCLUSIONS: Sildenafil treatment significantly decreased retinal vaso-obliteration and neovascularization in a mouse OIR model. These effects are likely due to sildenafil-induced HIF1α stabilization during hyperoxia exposure. Furthermore, we confirm disease overlap by showing that OIR mice also develop hyperoxia-induced right ventricular hypertrophy, which is prevented by sildenafil. This study is a first step toward delineating a potential therapeutic role for sildenafil in OIR and further suggests that there may be common pathophysiologic mechanisms underlying hyperoxia-induced retinal and pulmonary vascular disease.

Entities:  

Keywords:  mouse; neovascularization; retinopathy of prematurity; sildenafil; vaso-obliteration

Mesh:

Substances:

Year:  2014        PMID: 24519428      PMCID: PMC4586973          DOI: 10.1167/iovs.13-13207

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  61 in total

1.  Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension.

Authors:  C S Marsh; B Marden; R Newsom
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

2.  Light-induced reduction in cyclic GMP of retinal photoreceptor cells in vivo: abnormalities in the degenerative diseases of RCS rats and rd mice.

Authors:  D B Farber; R N Lolley
Journal:  J Neurochem       Date:  1977-05       Impact factor: 5.372

3.  Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice.

Authors:  L Wang; M Chopp; A Szalad; Z Liu; M Bolz; F M Alvarez; M Lu; L Zhang; Y Cui; R L Zhang; Z G Zhang
Journal:  Neuroscience       Date:  2011-07-27       Impact factor: 3.590

4.  Sildenafil therapy for bronchopulmonary dysplasia: not quite yet.

Authors:  K N Farrow; R H Steinhorn
Journal:  J Perinatol       Date:  2012-01       Impact factor: 2.521

5.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial.

Authors:  William V Good
Journal:  Trans Am Ophthalmol Soc       Date:  2004

6.  Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy.

Authors:  Jing Chen; Kip M Connor; Christopher M Aderman; Keirnan L Willett; Oskar P Aspegren; Lois E H Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

Review 7.  Proliferative retinopathies: angiogenesis that blinds.

Authors:  Przemyslaw Sapieha; David Hamel; Zhuo Shao; Jose Carlos Rivera; Karine Zaniolo; Jean Sébastien Joyal; Sylvain Chemtob
Journal:  Int J Biochem Cell Biol       Date:  2009-10-15       Impact factor: 5.085

8.  Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension.

Authors:  Robin H Steinhorn; John P Kinsella; Christine Pierce; Ghazwan Butrous; Maria Dilleen; Michael Oakes; David L Wessel
Journal:  J Pediatr       Date:  2009-12       Impact factor: 4.406

9.  Sildenafil (Viagra) evokes retinal arteriolar dilation: dual pathways via NOS activation and phosphodiesterase inhibition.

Authors:  Zhaoxu Yuan; Travis W Hein; Robert H Rosa; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

Review 10.  Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5.

Authors:  R H Cote
Journal:  Int J Impot Res       Date:  2004-06       Impact factor: 2.896

View more
  3 in total

Review 1.  Controversies in the identification and management of acute pulmonary hypertension in preterm neonates.

Authors:  Regan E Giesinger; Kiran More; Jodie Odame; Amish Jain; Robert P Jankov; Patrick J McNamara
Journal:  Pediatr Res       Date:  2017-10-04       Impact factor: 3.756

2.  Hyperoxia-Induced Proliferative Retinopathy: Early Interruption of Retinal Vascular Development with Severe and Irreversible Neurovascular Disruption.

Authors:  Michelle Lajko; Herminio J Cardona; Joann M Taylor; Ronil S Shah; Kathryn N Farrow; Amani A Fawzi
Journal:  PLoS One       Date:  2016-11-18       Impact factor: 3.240

3.  Photoreceptor oxidative stress in hyperoxia-induced proliferative retinopathy accelerates rd8 degeneration.

Authors:  Michelle Lajko; Herminio J Cardona; Joann M Taylor; Kathryn N Farrow; Amani A Fawzi
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.